Jason Harris

Ibrance Plus Faslodex May Improve Long-Term Survival for Advanced Breast Cancer

June 23, 2021

Article

The survival benefit obtained with Ibrance plus Faslodex persisted over a median follow-up of 73.3 months in patients with HR-positive, HER2-negative advanced breast cancer.

Higher Dose of Qinlock Improves Survival in Patients with Heavily Pretreated Advanced GIST

June 07, 2021

Article

Twice-daily treatment with Qinlock following disease progression after treatment with fourth-line therapy in patients with advanced gastrointestinal stromal tumor was associated with extended survival outcomes.

Obesity Linked With Higher Distress in Breast and Prostate Cancers

October 07, 2019

Article

Obese patients being treated for breast or prostate cancer showed higher levels of mental and physical distress than nonobese patients with these diseases, but the pattern did not hold true in those with colorectal cancer, according to a study.

First Multilingual App for Breast Exam Aims to Improve Early Detection

September 12, 2019

Article

The Pink Luminous Advocacy Project has introduced the Breast Awareness app, the first multilingual, unisex breast self-examination application.

Immunotherapy Researchers Win Nobel Prize

October 02, 2018

Article

Immunotherapy pioneers James P. Allison, Ph.D., and Tasuku Honjo, M.D., Ph.D., have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

Dream Team Evaluates Direct Testing of Tumors

July 15, 2018

Article

Investigators are learning how to take a tumor biopsy from a patient, grow small tumors called organoids in the lab, and test cancer treatments on them to see which work best.

Newly Diagnosed With Ovarian Cancer? Take a Breath, Then Follow These Steps

July 15, 2018

Article

The first thing a woman should do after receiving a diagnosis of ovarian cancer, according to Teresa P. Díaz-Montes, M.D., M.P.H., is nothing. At least not right away.

Venclexta and Imbruvica Combo Shows Promise in Mantle Cell Lymphoma

May 07, 2018

Article

A higher complete response rate was seen in patients given both agents compared with those given Imbruvica alone.

Xtandi Granted Priority Review for Prostate Cancer Treatment

March 20, 2018

Article

The Food and Drug Administration granted Xtandi (enzalutamide) a priority review to a supplemental new drug application for the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to the companies developing the drug, Pfizer and Astellas.

Drug Pair Is Promising in Metastatic Colorectal Cancer

March 19, 2018

Article

The combination induced a 31 percent disease control rate (DCR) in patients with heavily-pretreated metastatic colorectal cancer (mCRC).